Corporate$AMGN4:54 PM ET

Amgen to present Phase 3 data for dazodalibep in Sjögren's disease at ACR Convergence 2026

By BORSA NewsroomPublished Oct 27, 2026, 4:54 PM EDTUpdated Oct 27, 2026, 4:54 PM EDT

Amgen announced plans to present new data at ACR Convergence 2026, including Phase 3 OASIZ-301 results showing dazodalibep significantly reduced systemic disease activity and patient-reported dryness in Sjögren's disease. No FDA-approved treatments currently exist for Sjögren's.

Sentimentbullish 70

Bullish · 70 of 100

Impact50

low · stays off the top drivers

Confidence85%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Phase 3 OASIZ-301 met primary endpoint: dazodalibep reduced ESSDAI score vs placebo at Week 48